Angle (AGL)

 

AGL Share PerformanceMore

52 week high80.00 15/06/17
52 week low32.27 07/09/17
52 week change 0.50 (0.99%)
4 week volume2,746,792 30/04/18
price51.00
price date1527255643
close52.00

Media for (AGL)

Presenter: Andrew Newland, Chief Executive
10/10/2014

Latest NewsMore

Leading cancer surgeon appointed

RNS Number: 8891N Angle PLC 14 May 2018 For immediate release 14 May 2018 ANGLE plc ("the Company") LEADING NHS PROSTATE CANCER SURGEON APPOINTED AS SCIENTIFIC ADVISOR ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the appointment of Mr Greg L Shaw as a Scientific Adv...

Angle & QIAGEN Poster

RNS Number: 9525M Angle PLC 03 May 2018 For immediate release 3 May 2018 ANGLE plc ("the Company") ANGLE AND QIAGEN PRESENT POSTER AT LEADING CANCER CONFERENCE DEMONSTRATING UTILITY OF ANGLE'S PARSORTIX SYSTEM IN CONJUNCTION WITH QIAGEN'S ADNATEST ASSAY First joint marketing material relea...

Broker Forecast - finnCap issues a broker note on Angle PLC

finnCap today reaffirms its corporate investment rating on Angle PLC (LON:AGL) and set its price target at 108p. Broker F...

Angle reveals breakthrough in capturing cancer cells

Liquid biopsy Angle revealed Thursday the results of a recent study demonstrated a workflow for the recovery and cultu...

Parsortix in multiple presentations at AACR

RNS Number: 3941L Angle PLC 19 April 2018 For immediate release 19 April 2018 ANGLE plc ("the Company") ANGLE'S PARSORTIX SYSTEM SHOWCASED IN MULTIPLE PRESENTATIONS AT LEADING CANCER CONFERENCE AACR 2018 Customers and collaborators publish more successful research with ANGLE's Parsortix circulating tumor cell (CT...

Breakthrough Research with Parsortix

RNS Number: 3936L Angle PLC 19 April 2018 For immediate release 19 April 2018 ANGLE plc ("the Company") BREAKTHROUGH RESEARCH DEMONSTRATES PARSORTIX WORKFLOW FOR CULTURING CIRCULATING TUMOR CELLS FOR IN-VITRO DRUG TESTING Unique capabilities of ANGLE's Parsortix system address a key aim of precision m...

Angle enrols first patient into its study for metastatic breast cancer

Angle reported Thursday that the first patient was enrolled into its clinical study for metastatic breast cancer.

First patient enrolled in FDA study

RNS Number: 8764J Angle PLC 05 April 2018 For immediate release 5 April 2018 ANGLE plc ("the Company") FIRST PATIENT ENROLLED IN CLINICAL STUDY TO SUPPORT FDA CLEARANCE OF THE PARSORTIX SYSTEM FDA clearance would provide worldwide differentiation for the Parsortix system in the multi-billion dollar liquid biopsy market A...

Fundamental DataMore

EPS-8.71
Dividend yield0 %

Latest discussion posts More

  • Increasingly Frustrated ..

    With this share. Seems to hold immense potential and under 120 .million shares in issue. Regular stream of ?good news? but no major upward shift in price. I have repeatedly ...
    23-May-2018
    millwallfan
  • Re: More good news.

    Mmm. Rarely seems to be reflected in the SP. Still the latest target seems to be around 100p. Just gotta hold in there.
    3-May-2018
    claude reins
  • More good news.

    Collaborations coming together.
    3-May-2018
    autpaxautbellum

Users' HoldingsMore

Users who hold Angle also hold..

Codes & Symbols

ISINGB0034330679
SymbolsAGL, LSE:AGL, AGL.L, AGL:LN, LON:AGL, XLON:AGL